Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

Cell

Volumn 166, Issue 6, 2016, Pages 1459-1470.e11

  Briney, Bryan ^a   Sok, Devin ^a   Jardine, Joseph G ^a   Kulp, Daniel W ^a   Skog, Patrick ^a   Menis, Sergey ^a   Jacak, Ronald ^a   Kalyuzhniy, Oleksandr ^a   de Val, Natalia ^a   Sesterhenn, Fabian ^a   Le, Khoa M ^a   Ramos, Alejandra ^a   Jones, Meaghan ^a   Saye Francisco, Karen L ^a   Blane, Tanya R ^a   Spencer, Skye ^a   Georgeson, Erik ^a   Hu, Xiaozhen ^a   Ozorowski, Gabriel ^a   Adachi, Yumiko ^a   Kubitz, Michael ^a   Sarkar, Anita ^a   Wilson, Ian A ^a   Ward, Andrew B ^a   Nemazee, David ^a   Burton, Dennis R ^a,b   Schief, William R ^a,b   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VRC01 CLASS BROADLY NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIGEN;

ANTIBODY AFFINITY; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRAIT; GERMINAL CENTER; HEAVY CHAIN; HUMAN; IMMUNIZATION; MALE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; ADULT; AMINO ACID SEQUENCE; ANIMAL; B LYMPHOCYTE; BLOOD; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTATION; SEQUENCE ALIGNMENT; TRANSGENIC MOUSE;

ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; B-LYMPHOCYTES; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; SEQUENCE ALIGNMENT; VACCINES, SYNTHETIC;

EID: 84986296891     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.08.005     Document Type: Article

References (68)

1. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H.M., Kubo, R.T., Sette, A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1 (1994), 751–761.
2. Alexander, J., Fikes, J., Hoffman, S., Franke, E., Sacci, J., Appella, E., Chisari, F.V., Guidotti, L.G., Chesnut, R.W., Livingston, B., Sette, A., The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18 (1998), 79–92.
3. Andrabi, R., Voss, J.E., Liang, C.-H., Briney, B., McCoy, L.E., Wu, C.-Y., Wong, C.-H., Poignard, P., Burton, D.R., Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43 (2015), 959–973.
4. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.-W., Shekhar, K., Gupta, S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
5. Bhiman, J.N., Anthony, C., Doria-Rose, N.A., Karimanzira, O., Schramm, C.A., Khoza, T., Kitchin, D., Botha, G., Gorman, J., Garrett, N.J., et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21 (2015), 1332–1336.
6. Binley, J.M., Wrin, T., Korber, B., Zwick, M.B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004), 13232–13252.
7. Briney, B., Le, K., Zhu, J., Burton, D.R., Clonify: unseeded antibody lineage assignment from next-generation sequencing data. Sci. Rep., 6, 2016, 23901.
8. Briney, B.S., Willis, J.R., Crowe, J.E. Jr., Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity. Genes Immun. 13 (2012), 523–529.
9. Briney, B.S., Willis, J.R., McKinney, B.A., Crowe, J.E. Jr., High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals. Genes Immun. 13 (2012), 469–473.
10. Burton, D.R., Hangartner, L., Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34 (2016), 635–659.
11. Burton, D.R., Stanfield, R.L., Wilson, I.A., Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102 (2005), 14943–14948.
12. Caskey, M., Klein, F., Lorenzi, J.C.C., Seaman, M.S., West, A.P. Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
13. de Taeye, S.W., Moore, J.P., Sanders, R.W., HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol. 37 (2016), 221–232.
14. Dimitrov, D.S., Therapeutic antibodies, vaccines and antibodyomes. MAbs 2 (2010), 347–356.
15. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N.P., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
16. Diskin, R., Klein, F., Horwitz, J.A., Halper-Stromberg, A., Sather, D.N., Marcovecchio, P.M., Lee, T., West, A.P. Jr., Gao, H., Seaman, M.S., et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210 (2013), 1235–1249.
17. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
18. Falkowska, E., Le, K.M., Ramos, A., Doores, K.J., Lee, J.H., Blattner, C., Ramirez, A., Derking, R., van Gils, M.J., Liang, C.-H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40 (2014), 657–668.
19. Georgiev, I.S., Rudicell, R.S., Saunders, K.O., Shi, W., Kirys, T., McKee, K., O'Dell, S., Chuang, G.-Y., Yang, Z.-Y., Ofek, G., et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J. Immunol. 192 (2014), 1100–1106.
20. Gorman, J., Soto, C., Yang, M.M., Davenport, T.M., Guttman, M., Bailer, R.T., Chambers, M., Chuang, G.-Y., DeKosky, B.J., Doria-Rose, N.A., et al., NISC Comparative Sequencing Program. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23 (2016), 81–90.
21. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B., B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30 (2012), 423–433.
22. Hessell, A.J., Malherbe, D.C., Pissani, F., McBurney, S., Krebs, S.J., Gomes, M., Pandey, S., Sutton, W.F., Burwitz, B.J., Gray, M., et al. Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens. J. Immunol. 196 (2016), 3064–3078.
23. Hoot, S., McGuire, A.T., Cohen, K.W., Strong, R.K., Hangartner, L., Klein, F., Diskin, R., Scheid, J.F., Sather, D.N., Burton, D.R., Stamatatos, L., Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog., 9, 2013, e1003106.
24. Hraber, P., Korber, B.T., Lapedes, A.S., Bailer, R.T., Seaman, M.S., Gao, H., Greene, K.M., McCutchan, F., Williamson, C., Kim, J.H., et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J. Virol. 88 (2014), 12623–12643.
25. Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
26. Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog, P.D., Thinnes, T.C., Bhullar, D., Briney, B., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349 (2015), 156–161.
27. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
28. Jardine, J.G., Sok, D., Julien, J.-P., Briney, B., Sarkar, A., Liang, C.-H., Scherer, E.A., Henry Dunand, C.J., Adachi, Y., Diwanji, D., et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLoS Pathog., 2016, 10.1371/journal.ppat.1005815 Published online August 25, 2016.
29. Julien, J.-P., Cupo, A., Sok, D., Stanfield, R.L., Lyumkis, D., Deller, M.C., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1477–1483.
30. Kepler, T.B., Liao, H.-X., Alam, S.M., Bhaskarabhatla, R., Zhang, R., Yandava, C., Stewart, S., Anasti, K., Kelsoe, G., Parks, R., et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16 (2014), 304–313.
31. Kong, L., Ju, B., Chen, Y., He, L., Ren, L., Liu, J., Hong, K., Su, B., Wang, Z., Ozorowski, G., et al. Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. Immunity 44 (2016), 939–950.
32. Li, M., Gao, F., Mascola, J.R.J., Stamatatos, L., Polonis, V.R.V., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M.K., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005), 10108–10125.
33. Li, Y., Migueles, S.A.S., Welcher, B., Svehla, K., Phogat, A., Louder, M.K.M., Wu, X., Shaw, G.M.G., Connors, M., Wyatt, R.T., Mascola, J.R., Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 (2007), 1032–1034.
34. Li, Y., O'Dell, S., Walker, L.M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S.D., McKee, K., Louder, M.K., Ledgerwood, J.E., et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85 (2011), 8954–8967.
35. Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
36. Lyumkis, D., Julien, J.-P., de Val, N., Cupo, A., Potter, C.S., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., Carragher, B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1484–1490.
37. Ma, B.-J., Alam, S.M., Go, E.P., Lu, X., Desaire, H., Tomaras, G.D., Bowman, C., Sutherland, L.L., Scearce, R.M., Santra, S., et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog., 7, 2011, e1002200.
38. Martin, M., Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet 17 (2011), 10–12.
39. Mascola, J.R., Haynes, B.F., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254 (2013), 225–244.
40. Masella, A.P., Bartram, A.K., Truszkowski, J.M., Brown, D.G., Neufeld, J.D., PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics, 13, 2012, 31.
41. McGuire, A.T., Hoot, S., Dreyer, A.M., Lippy, A., Stuart, A., Cohen, K.W., Jardine, J., Menis, S., Scheid, J.F., West, A.P., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210 (2013), 655–663.
42. McGuire, A.T., Dreyer, A.M., Carbonetti, S., Lippy, A., Glenn, J., Scheid, J.F., Mouquet, H., Stamatatos, L., HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346 (2014), 1380–1383.
43. McGuire, A.T., Gray, M.D., Dosenovic, P., Gitlin, A.D., Freund, N.T., Petersen, J., Correnti, C., Johnsen, W., Kegel, R., Stuart, A.B., et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun., 7, 2016, 10618.
44. Pancera, M., McLellan, J.S., Wu, X., Zhu, J., Changela, A., Schmidt, S.D., Yang, Y., Zhou, T., Phogat, S., Mascola, J.R., Kwong, P.D., Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84 (2010), 8098–8110.
45. Pancera, M., Zhou, T., Druz, A., Georgiev, I.S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514 (2014), 455–461.
46. Pantaleo, G., Koup, R.A., Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10 (2004), 806–810.
47. Pegu, A., Yang, Z.-Y., Boyington, J.C., Wu, L., Ko, S.-Y., Schmidt, S.D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med., 6, 2014, 243ra88.
48. Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003), 4144–4149.
49. Rudicell, R.S., Kwon, Y.D., Ko, S.-Y., Pegu, A., Louder, M.K., Georgiev, I.S., Wu, X., Zhu, J., Boyington, J.C., Chen, X., et al., NISC Comparative Sequencing Program. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88 (2014), 12669–12682.
50. Sanders, R.W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Peña, A.T., Korzun, J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog., 9, 2013, e1003618.
51. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
52. Scharf, L., Scheid, J.F., Lee, J.H., West, A.P. Jr., Chen, C., Gao, H., Gnanapragasam, P.N.P., Mares, R., Seaman, M.S., Ward, A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7 (2014), 785–795.
53. Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y.K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
54. Seaman, M.S., Janes, H., Hawkins, N., Grandpre, L.E., Devoy, C., Giri, A., Coffey, R.T., Harris, L., Wood, B., Daniels, M.G., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84 (2010), 1439–1452.
55. Sellhorn, G., Kraft, Z., Caldwell, Z., Ellingson, K., Mineart, C., Seaman, M.S., Montefiori, D.C., Lagerquist, E., Stamatatos, L., Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J. Virol. 86 (2012), 128–142.
56. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M. Jr., Lifson, J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
57. Sok, D., van Gils, M.J., Pauthner, M., Julien, J.-P., Saye-Francisco, K.L., Hsueh, J., Briney, B., Lee, J.H., Le, K.M., Lee, P.S., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111 (2014), 17624–17629.
58. Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M.C., Wardemann, H., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329 (2008), 112–124.
59. Walker, L.M., Phogat, S.K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
60. Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al., Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477 (2011), 466–470.
61. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
62. West, A.P. Jr., Diskin, R., Nussenzweig, M.C., Bjorkman, P.J., Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 109 (2012), E2083–E2090.
63. Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
64. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., McKee, K., et al., NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 (2011), 1593–1602.
65. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.-Y., Longo, N.S., Dimitrov, D.S., Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390 (2009), 404–409.
66. Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 (2010), 811–817.
67. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.-Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.
68. Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al., NISC Comparative Sequencing Program. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161 (2015), 1280–1292.